NOV 28, 2015 6:11 AM PST

A Combination of Drugs and Immunotherapy To Treat Breast Cancer

WRITTEN BY: Kara Marker
The American Cancer Society predicts that over 40,000 women will die from breast cancer this year, and that's just in the United States. As motivated as ever, scientists from the University of Basel have developed a novel treatment plan to target breast cancer. 

With their results published in Science Translational Medicine, the team from Switzerland successfully created an "antibody-drug conjugate" (ADC) to pair with immunotherapy to attack cancerous cells. The ADC stimulates the immune system to bind to and kill tumor cells as they grow. 

The basis of the ADC mechanism comes from an observation of breast cell growth factors. About one-fifth of breast cancer patients show increased levels of human growth factor receptor 2 (HER2) on their tumor cell surfaces (breastcancer.org). Normal breast cell growth is harmless, but when too many HER2 genes are stimulating growth, cancer occurs. The ADC developed by the scientists from the University of Basel blocks the action of these malfunctioning receptors while simultaneously releasing cytotoxic chemicals that enter the tumor cell and instigate cell death.

In a study of mouse breast cancer models, the team combined ADC administration with immunotherapy treatments. By administering complementary antibodies to activate T lymphocytes, immunotherapy helps "reroute" the body's natural "immunoregulatory checkpoints" to ensure the right immune cells are being activated to fight the cancer. Without pairing immunotherapy with ADC treatment, T cell activation would not be as helpful. 

Combination therapy is a bright, new perspective for breast cancer treatment, and doctors like lead author Philipp Muller believe that "antibody-drug conjugates are suitable for use in a combination therapy."

Watch the following video to hear more about ADCs in detail.
Source: University of Basel
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
NOV 25, 2020
Immunology
Another COVID-19 vaccine shows promising results!
NOV 25, 2020
Another COVID-19 vaccine shows promising results!
A week ago, another biotechnology company "Moderna" announced the preliminary results from its COVID-19 vaccin ...
JAN 28, 2021
Neuroscience
Immune Cells Destroy Synapses in Multiple Sclerosis
JAN 28, 2021
Immune Cells Destroy Synapses in Multiple Sclerosis
Researchers from Germany have found that Multiple sclerosis (MS)-associated inflammation in the cerebral cortex destroys ...
FEB 03, 2021
Immunology
Severely Ill COVID-19 Patients may have Longer Immunity Against the Virus
FEB 03, 2021
Severely Ill COVID-19 Patients may have Longer Immunity Against the Virus
Researchers are still studying how long a person can stay immune against COVID-19 following infection. A new study by a ...
FEB 10, 2021
Drug Discovery & Development
Black Men Respond Best to Immunotherapy for Prostate Cancer
FEB 10, 2021
Black Men Respond Best to Immunotherapy for Prostate Cancer
Researchers from Northwestern University have found that Black men and men of African ancestry respond better than men f ...
FEB 18, 2021
Immunology
Protective COVID Antibodies Found in Breast Milk
FEB 18, 2021
Protective COVID Antibodies Found in Breast Milk
University of Rochester researchers analyzing breast milk samples from mothers with COVID-19 found that it doesn’t ...
MAR 02, 2021
Immunology
Another Trick up Tumors' Sleeves Exposed
MAR 02, 2021
Another Trick up Tumors' Sleeves Exposed
Tumors have sneaky strategies for establishing themselves within healthy tissues, flourishing in plain sight of circulat ...
Loading Comments...